In section Market Quotes

Belite Bio Falls 16% as FDA Extends Tinlarebant Review

Belite Bio shares fell 16% in morning trading after the FDA added three months to its review of the company’s application for tinlarebant, a treatment for Stargardt disease type 1. The stock traded at $127.11 and was down 20% year to date.

Belite Bio Falls 16% as FDA Extends Tinlarebant Review

The extended Prescription Drug User Fee Act action date is now May 12, 2027, Belite Bio said. The clinical-stage drug developer said the FDA needs more time to review information submitted in support of the new drug application.

If the agency identifies no major deficiencies during its ongoing review, it plans to communicate proposed labeling requests and any anticipated postmarketing requirement requests, if necessary, to the company by April 12, 2027.

Belite Bio said it is confident in the clinical evidence supporting tinlarebant and in the drug’s potential to address significant unmet medical need among people with STGD1.

Share:on TelegramXFacebook

Subscribe to our newsletter

Once a week — the best stories from our editors, no ads or push notifications. Delivered Sunday morning.

Comments (0)

Leave a comment

No comments yet. Be the first!